Affiliation:
1. From the Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University, Philadelphia, PA
2. Division of General Surgery, Department of Surgery, University of Vermont, Burlington, VT
3. Division of Cardiology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA
4. Division of Cardiac Surgery, Department of Surgery, University of Maryland, Baltimore, MD.
Abstract
Purpose:
We sought to characterize adaptive changes to the revised United Network for Organ Sharing donor heart allocation policy and estimate long-term survival trends for heart transplant (HTx) recipients.
Methods:
Patients listed for HTx between October 17, 2013 and September 30, 2021 were identified from the United Network for Organ Sharing database, and stratified into pre- and postpolicy revision groups. Subanalyses were performed to examine trends in device utilization for extracorporeal membranous oxygenation (ECMO), durable left ventricular assist device (LVAD), intra-aortic balloon pump (IABP), microaxial support (Impella), and no mechanical circulatory support (non-MCS). Survival data post-HTx were fitted to parametric distributions and extrapolated to 5 years.
Results:
We identified 27,523 HTx waitlist candidates during the study period, most of whom (n = 16,376) were waitlisted in the prepolicy change period. Overall, 19,554 patients underwent HTx during the study period (pre: 12,037 and post: 7517). Listings increased after the policy change for ECMO (P < 0.01), Impella (P < 0.01), and IABP (P < 0.01) patients. Listings for LVAD (P < 0.01) and non-MCS (P < 0.01) patients decreased. HTx increased for ECMO (P < 0.01), Impella (P < 0.01), and IABP (P < 0.01) patients after the policy change and decreased for LVAD (P < 0.01) and non-MCS (P < 0.01) patients. Waitlist survival increased for the overall (P < 0.01), ECMO (P < 0.01), IABP (P < 0.01), and non-MCS (P < 0.01) groups. Waitlist survival did not differ for the LVAD (P = 0.8) and Impella (P = 0.1) groups. Post-transplant survival decreased for the overall (P < 0.01), LVAD (P < 0.01), and non-MCS (P < 0.01) populations.
Conclusions:
Allocation policy revisions have contributed to greater utilization of ECMO, Impella, and IABP, decreased utilization of LVADs and non-MCS, increased waitlist survival, and decreased post-HTx survival.
Publisher
Ovid Technologies (Wolters Kluwer Health)